Grupo de Investigación en Cáncer de Mama
NEONCOBREAST
Gustave Roussy Cancer Campus
Villejuif, FranciaGustave Roussy Cancer Campus-ko ikertzaileekin lankidetzan egindako argitalpenak (9)
2024
-
Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature
Journal of Clinical Oncology, Vol. 42, Núm. 10, pp. 1124-1134
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
2021
-
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
The Lancet Oncology, Vol. 22, Núm. 4, pp. 476-488
-
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
European Journal of Cancer, Vol. 152, pp. 68-77
2020
-
Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial
Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197
2016
-
70-Gene signature as an aid to treatment decisions in early-stage breast cancer
New England Journal of Medicine, Vol. 375, Núm. 8, pp. 717-729
2015
-
Breast MRI: EUSOBI recommendations for women’s information
European Radiology, Vol. 25, Núm. 12, pp. 3669-3678
2011
-
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
European Journal of Cancer, Vol. 47, Núm. 18, pp. 2742-2749